In a study comparing adagrasib (an oral inhibitor of mutant KRAS G12C protein) in combination with intravenous cetuximab (an anti-EGFR monoclonal antibody) vs. adagrasib alone in previously treated patients with metastatic colorectal cancer with mutated KRAS G12C, a response rate of 46% and median PFS of 6.9 months were observed in the combination therapy group, compared with a response rate of 19% and a median PFS of 5.6 months in the monotherapy group86. This evidence concerns the gene KRAS and metastatic colorectal cancer.